Taken together, these in vitro studies showed that gene editing to remove the GAA hyper expansion is an efficient strategy for FRDA leading to increased FXN mRNA and protein expression, and cellular phenotype improvement, and CRISPR/Cas9 is particularly attractive for this purpose. The gene discussed is FXN; the disease is Friedreich ataxia.